Many pharmaceutical stocks such as Cylon Pharmaceutical and ST Kangmei closed at the limit higher

Recently, the pharmaceutical sector has pulled back, but there are still some pharmaceutical stocks that have performed well
.
According to the data of the Oriental Fortune Network Market Information Center, as of the close of November 25, Cylon Pharmaceutical, ST Kangmei closed up and down, in addition, Kangyuan Pharmaceutical, Saili Medical, etc.
rose by more than 2%.

Specifically, among the closing limit stocks, Cylon Pharmaceutical closed up more than 7% on the 25th, with a quotation of 14.
11 yuan, a turnover of 404 million, a turnover rate of 29.
55%, a loss in price-to-earnings (TTM), and a total market value of 2.
483 billion
.
The company is a characteristic innovative pharmaceutical enterprise, in recent years, the company has achieved fruitful research and development results, tranexamic acid injection, parecoxib sodium for injection, argatroban injection, thymus faxin for injection, tigecycline for injection and other new products have been approved one after another, and the R & D varieties are rich in reserves, providing inexhaustible power
for the company's long-term development 。 In terms of news, Cylon Pharmaceutical recently issued an announcement that the company recently received the "Notification Letter on Reducing the Proportion of Shares Held by More than 1%" issued by Cylon Juzhi, a shareholder holding more than 5% of the shares, and learned that following the company's previous disclosure of the "Announcement on Reducing the Number of Shares of Shareholders Holding More than 5% and Reducing Holdings by More than 1%", From March 12 to March 22, 2022, Cylon Juzhi reduced its holdings of 824,800 shares through centralized auction trading, and from June 24 to November 25, 2022, it reduced its holdings of 1.
02 million shares through centralized bidding, accounting for a total of 1.
05%
of the company's total share capital.
ST Kangmei closed at 2.
32 yuan on the 25th, up nearly 5%, with a turnover of 680 million, a turnover rate of 2.
20%, a price-to-earnings (TTM) of 3.
99, and a total market value of 32.
164 billion
.
It is worth mentioning that the stock has risen 19 times
in the past year.
The company is an enterprise
mainly producing and selling Chinese medicine pieces.
The business system covers upstream authentic Chinese herbal medicine planting, fresh processing and resource integration in the production area; Midstream professional market operation of Chinese medicinal materials, production and sales of Chinese medicine pieces, Chinese proprietary medicine preparations, health food, chemicals and medical devices, modern pharmaceutical logistics system; The downstream all-round multi-level marketing network integrating medical institution resources, smart pharmacies, OTC retail, chain pharmacies, direct sales, pharmaceutical e-commerce, and mobile medical care
.
In recent years, the state has attached great importance to the development of the traditional Chinese medicine industry and issued a series of favorable policies to support and encourage development
.
For example, the "14th Five-Year Plan" for the development of Chinese medicine issued in March requires that both Chinese and Western medicine be adhered to, inheriting the essence, keeping the right innovation, implementing major projects for the revitalization and development of Chinese medicine, and putting forward specific development goals and key tasks
.
In November, multiple departments issued the "Opinions on Strengthening the Work of Chinese Medicine Talents in the New Era", which proposed relevant measures from the aspects of attracting, agglomerating, motivating talents and strengthening platform construction, so as to provide strong talent support and intellectual guarantee
for the revitalization and development of Chinese medicine.
On November 11, the National Health Commission issued another notice, mentioning that it is necessary to pay attention to giving full play to the unique advantages of traditional Chinese medicine and make a reserve
of effective traditional Chinese medicine prescription drugs.
Under the influence of good news, the overall performance of the traditional Chinese medicine sector has been strong this year, and it has repeatedly set off the tide of ups and downs, among which Yiling Pharmaceutical walked out of 4 days and 3 boards, Teyi Pharmaceutical has repeatedly risen and stopped, and Chinese medicine ETF has also risen
.
Looking forward to the future market, CITIC Securities believes that in recent years, the state has vigorously supported the development of traditional Chinese medicine, and has continuously introduced relevant support policies, and the long-term development of traditional Chinese medicine has improved
.
At the same time, traditional Chinese medicine has the attributes of consumer goods and health care products, and has a long-term growth logic
under the aging of the population and consumption upgrading.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.